Oxbryta
Payments companies reported to CMS as associated with Oxbryta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Oxbryta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Oxbryta
These are the largest totals companies reported as associated with Oxbryta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Nirmish Shah | Durham, NC | Internal Medicine | $182,749.33 |
| Santosh Saraf | Chicago, IL | Hematology & Oncology | $59,924.96 |
| Wanda Whitten-Shurney | Detroit, MI | Pediatrics | $57,280.38 |
| Artangela Henry | Memphis, TN | Adult Health (Nurse Practitioner) | $54,179.11 |
| Richard Drachtman | New Brunswick, NJ | Pediatric Hematology-Oncology | $40,421.11 |
| Tobenna Nwizu | Rowlett, TX | Hematology & Oncology | $35,144.31 |
| Patricia Adams-Graves | Memphis, TN | Hematology & Oncology | $32,310.15 |
| Alan Anderson | Greenville, SC | Pediatric Hematology-Oncology | $30,907.22 |
| William Ershler | Fairfax, VA | Hematology & Oncology | $30,303.84 |
| Sanaa Rizk | Philadelphia, PA | Hematology (Internal Medicine) | $29,942.32 |
Prescribed Oxbryta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.